|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1991-9-11
|
|
pubmed:abstractText |
T and B cell human responses to European bat lyssavirus (EBL1) induced by post-exposure rabies vaccination (PM virus vaccine) were evaluated by measuring plasmatic titres of EBL1-specific neutralizing antibodies; specific EBL1-binding antibodies; and proliferation indices of peripheral blood lymphocytes stimulated in vitro with EBL1. These parameters for vaccination efficacy were compared with those obtained with vaccine-related viruses (CVS and ERA) and with a non-vaccine-related virus. Mokola virus, the last implicated in vaccination failures. Twenty-two patients exposed to rabies risk who received a reduced rabies post-exposure vaccination were involved in the study. On day 21, vaccine induced CVS-specific neutralizing antibodies in all patients; but EBL1-specific neutralizing antibodies were induced in only 73% of patients. No vaccine had Mokola-specific neutralizing antibodies. Patients having EBL1-specific neutralizing antibodies were usually those in whom vaccination induced high titres of CVS-specific neutralizing antibodies. On day 21, peripheral blood lymphocytes of 86% of patients could be restimulated in vitro with vaccine, 43% with EBL1 and 45% with Mokola. Patients exhibiting a high vaccine-specific proliferation response more likely developed an EBL1- or a Mokola-specific proliferative response. No correlation was found between T and B cell responses. Rabies vaccination induced neither T nor B cell EBL1-specific responses in 22% of patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-1087335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-14907713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-193466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2391499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2457112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2461007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2471814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2576595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2760222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2868310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-2875263,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-3206089,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-3420976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-3480536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-3655404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-376938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-387798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-4074475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-4219507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-4266465,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-4568184,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-479638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-6163717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-6171709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-6181927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-6526138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-7043888,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-833940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1864001-911112
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
224-30
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1864001-Adult,
pubmed-meshheading:1864001-Animals,
pubmed-meshheading:1864001-Antibodies, Viral,
pubmed-meshheading:1864001-Antibody Specificity,
pubmed-meshheading:1864001-B-Lymphocytes,
pubmed-meshheading:1864001-Chiroptera,
pubmed-meshheading:1864001-Female,
pubmed-meshheading:1864001-Humans,
pubmed-meshheading:1864001-Lymphocyte Activation,
pubmed-meshheading:1864001-Male,
pubmed-meshheading:1864001-Middle Aged,
pubmed-meshheading:1864001-Neutralization Tests,
pubmed-meshheading:1864001-Rabies Vaccines,
pubmed-meshheading:1864001-Rhabdoviridae,
pubmed-meshheading:1864001-Species Specificity,
pubmed-meshheading:1864001-T-Lymphocytes
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.
|
|
pubmed:affiliation |
Unité de la Rage, Hôpital Pasteur, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
